{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03539744","nct_id":"NCT03539744","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03539744. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Venetoclax administered orally once daily (QD) plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.","label":"Arm 1 VenDex","type":"EXPERIMENTAL"},{"description":"Pomalidomide administered orally once daily (QD) on Days 1 - 21 for each 28-day cycle plus dexamethasone administered orally once every week (Q1W) for each 28-day cycle.","label":"Arm 2 PomDex","type":"ACTIVE_COMPARATOR"}],"collaborators":["Roche-Genentech"],"completion_date":{"date":"2027-11","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":265,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pomalidomide","otherNames":["Pomalyst"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Venetoclax","otherNames":["ABT-199","GDC-0199"],"type":"DRUG"}],"last_update":"2025-06-19","lead_sponsor":"AbbVie","official_title":"A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 43 months from first randomization"}],"references":[{"citation":"Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, Jo JC, Kapoor P, Katodritou E, Kortum KM, Ling S, Nagarajan C, Suzuki K, Qiu L, Onishi M, Ku G, Dail M, Mukherjee N, Ross JA, Badawi MA, Fusco MJ, Dobkowska E, Arriola E, Bueno OF, Bahlis NJ, Iida S, Moreau P, Valent J, Mateos MV. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. J Clin Oncol. 2026 Jan 20;44(3):164-175. doi: 10.1200/JCO-25-00924. Epub 2025 Dec 10.","pmid":"41370738","type":"DERIVED"}],"start_date":{"date":"2018-10-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.","url":"https://clinicaltrials.gov/study/NCT03539744"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03539744"}